BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 33214069)

  • 21. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of
    Levis MJ; Hamadani M; Logan B; Jones RJ; Singh AK; Litzow M; Wingard JR; Papadopoulos EB; Perl AE; Soiffer RJ; Ustun C; Ueda Oshima M; Uy GL; Waller EK; Vasu S; Solh M; Mishra A; Muffly L; Kim HJ; Mikesch JH; Najima Y; Onozawa M; Thomson K; Nagler A; Wei AH; Marcucci G; Geller NL; Hasabou N; Delgado D; Rosales M; Hill J; Gill SC; Nuthethi R; King D; Wittsack H; Mendizabal A; Devine SM; Horowitz MM; Chen YB;
    J Clin Oncol; 2024 May; 42(15):1766-1775. PubMed ID: 38471061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.
    Mosquera Orgueira A; Bao Pérez L; Mosquera Torre A; Peleteiro Raíndo A; Cid López M; Díaz Arias JÁ; Ferreiro Ferro R; Antelo Rodríguez B; González Pérez MS; Albors Ferreiro M; Alonso Vence N; Pérez Encinas MM; Bello López JL; Martinelli G; Cerchione C
    Minerva Med; 2020 Oct; 111(5):427-442. PubMed ID: 32955823
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Positive Minimal Residual Disease of FLT3-ITD before Hematopoietic Stem Cell Transplantation Resulted in a Poor Prognosis of an Acute Myeloid Leukemia.
    Iwasaki Y; Nishiuchi R; Aoe M; Takahashi T; Watanabe H; Tokorotani C; Kikkawa K; Shimada A
    Acta Med Okayama; 2017 Feb; 71(1):79-83. PubMed ID: 28238014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation.
    Zhang Z; Hasegawa Y; Hashimoto D; Senjo H; Kikuchi R; Chen X; Yoneda K; Sekiguchi T; Kawase T; Tsuzuki H; Ishio T; Ara T; Ohigashi H; Nakagawa M; Teshima T
    Bone Marrow Transplant; 2022 May; 57(5):775-780. PubMed ID: 35228711
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia.
    Hosono N; Yokoyama H; Aotsuka N; Ando K; Iida H; Ishikawa T; Usuki K; Onozawa M; Kizaki M; Kubo K; Kuroda J; Kobayashi Y; Shimizu T; Chiba S; Nara M; Hata T; Hidaka M; Fujiwara SI; Maeda Y; Morita Y; Kusano M; Lu Q; Miyawaki S; Berrak E; Hasabou N; Naoe T
    Int J Clin Oncol; 2021 Nov; 26(11):2131-2141. PubMed ID: 34363558
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [FLT3-ITD mutation-positive acute myeloid leukemia undergoing clonal transition with PTPN11 mutation at relapse].
    Kurihara K; Sadato D; Najima Y; Hirama C; Haraguchi K; Kato K; Kondo K; Sadaga Y; Kato C; Sakai S; Kambara Y; Nabe Y; Teshima K; Asano K; Jinguji A; Shimabukuro M; Ouchi F; Inai K; Koi S; Shingai N; Toya T; Shimizu H; Kobayashi T; Oboki K; Harada H; Okuyama Y; Harada Y; Doki N
    Rinsho Ketsueki; 2024; 65(2):63-68. PubMed ID: 38447999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete remission: a retrospective study.
    Nasilowska-Adamska B; Czyz A; Markiewicz M; Rzepecki P; Piatkowska-Jakubas B; Paluszewska M; Dzierzak-Mietla M; Solarska I; Borg K; Prochorec-Sobieszek M; Szydlo R; Lewandowski K; Skotnicki A; Jedrzejczak WW; Kyrcz-Krzemien S; Komarnicki M; Warzocha K
    Eur J Haematol; 2016 Mar; 96(3):236-44. PubMed ID: 25912052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcome of Childhood Acute Myeloid Leukemia With FLT3-ITD Mutation: The Experience of Children's Cancer Hospital Egypt, 2007-17.
    Semary SF; Hammad M; Soliman S; Yassen D; Gamal M; Albeltagy D; Hamdy N; Mahmoud S
    Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):e529-e541. PubMed ID: 32473792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation.
    Lee JK; Chatterjee A; Scarpa M; Bailey CM; Niyongere S; Singh P; Mustafa Ali MK; Kapoor S; Wang Y; Silvestri G; Baer MR
    Cancer Res Commun; 2024 Feb; 4(2):431-445. PubMed ID: 38284896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A budget impact analysis of gilteritinib for the treatment of relapsed or refractory
    Pandya BJ; Yang H; Schmeichel C; Qi CZ; Shah MV
    J Med Econ; 2021; 24(1):19-28. PubMed ID: 33280474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical outcome of FLT3-ITD (+) acute myeloid leukemia patients treated with allogeneic hematopoietic stem cell transplantation].
    Yang Z; Tian H; Xu Y; Qiu H; Chen S; Sun A; Wu D
    Zhonghua Nei Ke Za Zhi; 2014 Feb; 53(2):94-8. PubMed ID: 24767158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gilteritinib monotherapy for relapsed/refractory FLT3 mutated acute myeloid leukemia: a real-world, multi-center, matched analysis.
    Shimony S; Canaani J; Kugler E; Nachmias B; Ram R; Henig I; Frisch A; Ganzel C; Vainstein V; Moshe Y; Aumann S; Yeshurun M; Ofran Y; Raanani P; Wolach O
    Ann Hematol; 2022 Sep; 101(9):2001-2010. PubMed ID: 35739428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with
    Levis MJ; Perl AE; Altman JK; Gocke CD; Bahceci E; Hill J; Liu C; Xie Z; Carson AR; McClain V; Stenzel TT; Miller JE
    Blood Adv; 2018 Apr; 2(8):825-831. PubMed ID: 29643105
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in
    Dumas PY; Villacreces A; Guitart AV; El-Habhab A; Massara L; Mansier O; Bidet A; Martineau D; Fernandez S; Leguay T; Pigneux A; Vigon I; Pasquet JM; Desplat V
    Clin Cancer Res; 2021 Nov; 27(21):6012-6025. PubMed ID: 34400415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.
    De Freitas T; Marktel S; Piemontese S; Carrabba MG; Tresoldi C; Messina C; Lupo Stanghellini MT; Assanelli A; Corti C; Bernardi M; Peccatori J; Vago L; Ciceri F
    Eur J Haematol; 2016 Jun; 96(6):629-36. PubMed ID: 26260140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gilteritinib as Bridging and Posttransplant Maintenance for Relapsed Acute Myeloid Leukemia with FLT3-ITD Mutation Accompanied by Extramedullary Disease in Elderly.
    Saburi M; Sakata M; Maruyama R; Kodama Y; Takata H; Miyazaki Y; Kawano K; Wada J; Urabe S; Ohtsuka E
    Case Rep Hematol; 2023; 2023():7164742. PubMed ID: 37662831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
    Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
    Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia].
    Kawashima N
    Rinsho Ketsueki; 2021; 62(8):954-966. PubMed ID: 34497236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
    Zhang C; Lam SSY; Leung GMK; Tsui SP; Yang N; Ng NKL; Ip HW; Au CH; Chan TL; Ma ESK; Yip SF; Lee HKK; Lau JSM; Luk TH; Li W; Kwong YL; Leung AYH
    Cancer; 2020 Jan; 126(2):344-353. PubMed ID: 31580501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.